oncology– tag –

Antibody-drug conjugates (ADCs) have emerged as one of the most exciting modalities in oncology. Among them, HER2-targeted ADCs have undergone a dramatic transformation with the arrival of Daiichi Sankyo and AstraZeneca’s Enhertu, sparki...

This series provides an in-depth review of the current landscape of Claudin18.2 (CLDN18.2)-targeted antibody–drug conjugates (ADCs) in gastric and gastroesophageal junction (GEJ) cancers. Structured into five parts, it covers pivotal cli...

Across pancreatic ductal adenocarcinoma (PDAC) models, tumor cells show marked intercellular heterogeneity in stress granules (SGs). A single-cell, cell-cycle–aware view reveals that SGs are maximally enriched in G2, powered by a lipid m...

In recent years, cancer and aging have increasingly been understood not as separate biological phenomena, but as interconnected processes. Immune decline and chronic inflammation in cancer patients may not be caused solely by treatment s...

Last updated: 2025-09-01 JST Lead: The shift from ex vivo to in vivo CAR-T is turning into a full-blown race. Big-ticket M&A, first-patient-dosed milestones, and multiple Phase-1 entries are consolidating the field into two lanes: le...

Appendix: IL-6R Inhibitors & Company Landscape (as of Aug 2025) A quick map of who owns which IL-6R blockers and current approved uses, to inform combo trials and partnering around the neuro-immune loop discussed above. Approved agen...

Fresh data in Science Signaling (2025) show that tumor-derived small extracellular vesicles (sEVs) reprogram TRPV1+ nociceptors, boosting IL-6 and Substance P, thereby increasing MDSC infiltration and CD8 T-cell exhaustion—a neuro-immune...

Introduction: Why Pancreatic Cancer Is So Difficult to Treat Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a dismal 5-year survival rate of about 10%. Three major challenges underlie this poor ...

Trilogy Subtitles＋Series Summary Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generatio...

Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design...

Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design...

Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design...

This article is the second half of the Morningglorysciences Summer Beginner Series Grand Summary. In Part 1, we reviewed anti-obesity drugs, ADCs, and In vivo CAR-T cell therapy, comparing their strengths and shared challenges. Here in P...

Recent research highlights that aging and obesity each independently promote cancer progression and can act synergistically to worsen outcomes. However, weight loss appears capable of rejuvenating immune function and suppressing tumor gr...

This article is the first half of the Morningglorysciences Summer Beginner Series Grand Summary. We revisit three major therapeutic modalities—anti-obesity drugs, antibody-drug conjugates (ADCs), and In vivo CAR-T cell therapy—highlighti...

This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on “In vivo CAR-T.” Previous articles covered the basics, leading researchers and companies, technical challenges, and global partnerships. Here...

This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on Antibody-Drug Conjugates (ADCs). Throughout the series, we introduced the basics, design principles, historical improvements, and clinical ap...

In this final deep-dive of our beginner-friendly bispecific antibody series, we explore the historical trajectory of bispecific antibody (BsAb) technology. From early-stage instability to today’s modular, multifunctional platforms, the e...

In this final volume, we summarize the latest developments in bispecific antibody drug R&D by leading biotech and pharma companies, as well as major approvals over the past year in the US and EU. We also highlight key trends and nota...

Even among bispecific antibody drugs, the pharmacological behavior in the body can vary significantly depending on the structural modality. This article explains in simple terms how differences in modalities—such as IgG-based, non-IgG, a...